Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases

Open access

Published version of a preprint

Abstract

Genetic diseases are leading causes of childhood mortality. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are relatively new methods for diagnosing genetic diseases, whereas chromosomal microarray (CMA) is well established. Here we compared the diagnostic utility (rate of causative, pathogenic, or likely pathogenic genotypes in known disease genes) and clinical utility (proportion in whom medical or surgical management was changed by diagnosis) of WGS, WES, and CMA in children with suspected genetic diseases by systematic review of the literature (January 2011–August 2017) and meta-analysis, following MOOSE/PRISMA guidelines. In 37 studies, comprising 20,068 children, diagnostic utility of WGS (0.41, 95% CI 0.34–0.48, I 2 = 44%) and WES (0.36, 95% CI 0.33–0.40, I 2 = 83%) were qualitatively greater than CMA (0.10, 95% CI 0.08–0.12, I 2 = 81%). Among studies published in 2017, the diagnostic utility of WGS was significantly greater than CMA ( P < 0.0001, I 2 = 13% and I 2 = 40%, respectively). Among studies featuring within-cohort comparisons, the diagnostic utility of WES was significantly greater than CMA ( P < 0.001, I 2 = 36%). The diagnostic utility of WGS and WES were not significantly different. In studies featuring within-cohort comparisons of WGS/WES, the likelihood of diagnosis was significantly greater for trios than singletons (odds ratio 2.04, 95% CI 1.62–2.56, I 2 = 12%; P < 0.0001). Diagnostic utility of WGS/WES with hospital-based interpretation (0.42, 95% CI 0.38–0.45, I 2 = 48%) was qualitatively higher than that of reference laboratories (0.29, 95% CI 0.27–0.31, I 2 = 49%); this difference was significant among studies published in 2017 ( P < .0001, I 2 = 22% and I 2 = 26%, respectively). The clinical utility of WGS (0.27, 95% CI 0.17–0.40, I 2 = 54%) and WES (0.17, 95% CI 0.12–0.24, I 2 = 76%) were higher than CMA (0.06, 95% CI 0.05–0.07, I 2 = 42%); this difference was significant for WGS vs CMA ( P < 0.0001). In conclusion, in children with suspected genetic diseases, the diagnostic and clinical utility of WGS/WES were greater than CMA. Subgroups with higher WGS/WES diagnostic utility were trios and those receiving hospital-based interpretation. WGS/WES should be considered a first-line genomic test for children with suspected genetic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41525-018-0053-8

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparison of diagnostic (Dx) utility of WGS, WES and CMA. a The pooled diagnostic utility of WGS and WES were both greater than of CMA. However, severe heterogeneity precluded quantitative analysis. b The subset of studies published in 2017 showed reduced heterogeneity for all subgroups. The pooled diagnostic utility with WGS was significantly higher than with CMA (P < 0.0001). c Among manuscripts that provided complete data for the frequency of diagnoses made by WES and CMA, the pooled odds of diagnosis was 8.3 times greater for WGS (P < 0.0001)
Fig. 1 Comparison of diagnostic (Dx) utility of WGS, WES and CMA. a The pooled diagnostic utility of WGS and WES were both greater than of CMA. However, severe heterogeneity precluded quantitative analysis. b The subset of studies published in 2017 showed reduced heterogeneity for all subgroups. The pooled diagnostic utility with WGS was significantly higher than with CMA (P < 0.0001). c Among manuscripts that provided complete data for the frequency of diagnoses made by WES and CMA, the pooled odds of diagnosis was 8.3 times greater for WGS (P < 0.0001)CC BY · PubMed Central
Fig. 2 Exploration of heterogeneity of diagnostic utility in WGS and WES studies. a Meta-regression scatterplot for study size. On average, an increase of 1000 subjects decreased the odds of diagnosis by 28% (P = 0.01). Size of data point corresponds to the study’s inverse-variance weight. b Meta-regression scatterplot for diagnostic utility of WGS/WES vs year of study publication. On average, the odds of diagnosis increased by 16% per annum since 2013 (P = 0.01). c Meta-regression scatterplot for the diagnostic utility of CMA vs year of study publication. The odds of diagnosis decreased by an average of 14% per year between 2013 and 2017 (P < 0.001). d The rate of diagnosis associated with de novo variation varied inversely with consanguinity. On average, increasing the rate of consanguinity by 10% decreased the odds of de novo variant diagnoses by 21% (P < 0.001)
Fig. 2 Exploration of heterogeneity of diagnostic utility in WGS and WES studies. a Meta-regression scatterplot for study size. On average, an increase of 1000 subjects decreased the odds of diagnosis by 28% (P = 0.01). Size of data point corresponds to the study’s inverse-variance weight. b Meta-regression scatterplot for diagnostic utility of WGS/WES vs year of study publication. On average, the odds of diagnosis increased by 16% per annum since 2013 (P = 0.01). c Meta-regression scatterplot for the diagnostic utility of CMA vs year of study publication. The odds of diagnosis decreased by an average of 14% per year between 2013 and 2017 (P < 0.001). d The rate of diagnosis associated with de novo variation varied inversely with consanguinity. On average, increasing the rate of consanguinity by 10% decreased the odds of de novo variant diagnoses by 21% (P < 0.001)CC BY · PubMed Central
Fig. 3 Comparison of diagnostic (Dx) utility of singleton and trio WGS/WES in studies where both analyses were performed. In five studies that conducted within-cohort comparisons of singleton and trio genomic sequencing, the pooled odds of diagnosis for trios was twice that of singletons (P < 0.0001)
Fig. 3 Comparison of diagnostic (Dx) utility of singleton and trio WGS/WES in studies where both analyses were performed. In five studies that conducted within-cohort comparisons of singleton and trio genomic sequencing, the pooled odds of diagnosis for trios was twice that of singletons (P < 0.0001)CC BY · PubMed Central
Fig. 4 Comparison of diagnostic (Dx) utility of WGS/WES in hospital laboratories and reference laboratories. a The pooled diagnostic utility of hospital-based testing was greater than reference laboratory testing. However, substantial heterogeneity was observed. b The subset of studies published in 2017 showed reduced heterogeneity for both subgroups. The pooled diagnostic utility was significantly greater in hospitals than in reference laboratories (P = 0.004)
Fig. 4 Comparison of diagnostic (Dx) utility of WGS/WES in hospital laboratories and reference laboratories. a The pooled diagnostic utility of hospital-based testing was greater than reference laboratory testing. However, substantial heterogeneity was observed. b The subset of studies published in 2017 showed reduced heterogeneity for both subgroups. The pooled diagnostic utility was significantly greater in hospitals than in reference laboratories (P = 0.004)CC BY · PubMed Central
Fig. 5 Comparison of the rate of clinical utility of WGS, WES, and CMA. The rate of clinical utility was the proportion of children tested who received a change in medical or surgical management as a result of genetic disease diagnosis. The pooled rate of clinical utility of WGS and WES were both greater than of CMA. However, there was severe heterogeneity in the WES subgroup. Testing for subgroup differences amongst groups with low to moderate heterogeneity, we found that WGS diagnoses lead to an improved rate of clinical utility over CMA diagnoses
Fig. 5 Comparison of the rate of clinical utility of WGS, WES, and CMA. The rate of clinical utility was the proportion of children tested who received a change in medical or surgical management as a result of genetic disease diagnosis. The pooled rate of clinical utility of WGS and WES were both greater than of CMA. However, there was severe heterogeneity in the WES subgroup. Testing for subgroup differences amongst groups with low to moderate heterogeneity, we found that WGS diagnoses lead to an improved rate of clinical utility over CMA diagnosesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Research works printed but not linked: 1

  1. Schwarzer, G. meta: an R package for meta-analysis. R. News 7, 40–45 (2007).

Cited by

See all 624

Metadata

Authors
Clark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & Kingsmore, S. F.
Affiliations
  • Rady Children's Institute for Genomic Medicine (US)
  • Murdoch Children's Research Institute (AU)
  • University of California San Diego (US)
  • The University of Melbourne (AU)
Corresponding author
Kingsmore, Stephen F.
Venue
npj Genomic Medicine
Published
2018-07-09
Volume
3
Issue
1
Pages
16-16
ISSN
2056-7944 (ISSN-L)
OpenAlex
W2805193585
Cited by
619
References
74
Citations by year
2026: 49 · 2025: 74 · 2024: 80 · 2023: 83 · 2022: 100 · 2021: 98 · 2020: 83 · 2019: 44 · 2018: 6
FWCI
7.96
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Genomic Medicine (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • National Human Genome Research Institute
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (U19HD077693)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
whole genome sequencing, exome sequencing, chromosomal microarray analysis, genetic diagnosis, diagnostic yield, clinical utility, genetic interpretation, pathogenic variants, pediatric genetics, rare genetic disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. https://app.cochat.ai/papers/10.1038/s41525-018-0053-8
The paper
Clark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & Kingsmore, S. F. (2018). Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. npj Genomic Medicine. https://doi.org/10.1038/s41525-018-0053-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.